Evidence map›Paper›PMID 26337942›Full record

ReviewGastroenterology report2015

Molecular phenotypes of colorectal cancer and potential clinical applications.

Jonathan M Kocarnik, Stacey Shiovitz, Amanda I Phipps

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology report, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 3 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 3 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Observational
  6. Review
  7. Article
  8. Observational
  9. Waist Circumference, a Body Shape Index, and Molecular Subtypes of Colorectal Cancer: A Pooled Analysis of Four Cohort Studies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jonathan M KocarnikPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, Epidemiology Department, University of Washington, Seattle, WA, USA.
Stacey ShiovitzClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA and Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Amanda I PhippsPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, Epidemiology Department, University of Washington, Seattle, WA, USA, aiphipps@uw.edu.
Fred Hutch Cancer Center · USUniversity of Washington Medical Center · US

Funding

TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
Lifestyle Factors and Survival Outcomes for Colorectal Cancer Molecular SubtypesK07CA172298 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PHIPPS, AMANDA IRENE · 2013 to 2016
$406k
NCI NIH HHS K07 CA172298NCI NIH HHS T32 CA009515
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a heterogeneous disease, arising from many possible etiological pathways. This heterogeneity can have important implications for CRC prognosis and clinical management. Epidemiological studies of CRC risk and prognosis-as well as clinical trials for the treatment of CRC-must therefore be sensitive to the molecular phenotype of colorectal tumors in patients under study. In this review, we describe four tumor markers that have been widely studied as reflections of CRC heterogeneity: (i) microsatellite instability (MSI) or DNA mismatch repair (MMR) deficiency, (ii) the CpG island methylator phenotype (CIMP), and somatic mutations in (iii) BRAF and (iv) KRAS. These tumor markers have been used to better characterize CRC epidemiology and, increasingly, may be used to guide clinical decision-making. Going beyond these traditional tumor markers, we also briefly review some more novel markers likely to be of clinical significance. Lastly, recognizing that none of these individual tumor markers are isolated attributes but, rather, a reflection of broader tumor phenotypes, we review some of the hypothesized etiological pathways of CRC development and their associated clinical differences.

Indexed as

BRAFcolorectal cancerCpG island methylator phenotypeepidemiologyKRASmicrosatellite instabilitytreatment

Identifiers

PMID26337942
PMCPMC4650976
OpenAlexW2244314249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.